Johnson & Johnson Debt-to-EBITDA Ratio Growth & History (JNJ)
Johnson & Johnson's debt-to-ebitda ratio was 1.20 for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-28 | 1.20 | −0.33 | −21.32% |
| 2024 | 2024-12-29 | 1.53 | 0.22 | +16.86% |
| 2023 | 2023-12-31 | 1.31 | −0.23 | −15.15% |
| 2022 | 2023-01-01 | 1.54 | — | — |
| 2014 | 2014-12-28 | 0.73 | −0.15 | −17.32% |
| 2013 | 2013-12-29 | 0.89 | 0.02 | +2.19% |
| 2012 | 2012-12-30 | 0.87 | −0.29 | −25.20% |
| 2011 | 2012-01-01 | 1.16 | 0.35 | +43.16% |
| 2010 | 2011-01-02 | 0.81 | 0.06 | +7.82% |
| 2009 | 2010-01-03 | 0.75 | — | — |
Johnson & Johnson quarterly debt-to-ebitda ratio
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | 1.44 | — | — |
| Q1 2026 | 2026-03-29 | 1.63 | — | — |
| Q1 2015 | 2015-03-29 | 0.74 | −0.06 | −6.90% |
| Q4 2014 | 2014-12-28 | 0.73 | −0.15 | −17.32% |
| Q3 2014 | 2014-09-28 | 0.60 | −0.13 | −18.14% |
| Q2 2014 | 2014-06-29 | 0.76 | 0.04 | +5.43% |
| Q1 2014 | 2014-03-30 | 0.80 | −0.07 | −8.40% |
| Q4 2013 | 2013-12-29 | 0.89 | 0.02 | +2.19% |
| Q3 2013 | 2013-09-29 | 0.73 | −0.33 | −31.16% |
| Q2 2013 | 2013-06-30 | 0.72 | −0.34 | −31.97% |
| Q1 2013 | 2013-03-31 | 0.87 | −0.25 | −22.28% |
| Q4 2012 | 2012-12-30 | 0.87 | −0.29 | −25.20% |
| Q3 2012 | 2012-09-30 | 1.06 | — | — |
| Q2 2012 | 2012-07-01 | 1.06 | — | — |
| Q1 2012 | 2012-04-01 | 1.12 | — | — |
| Q4 2011 | 2012-01-01 | 1.16 | — | — |
Johnson & Johnson debt-to-ebitda ratio trends
Between the periods ended 2010-01-03 and 2025-12-28, Johnson & Johnson's debt-to-ebitda ratio increased from 0.75 to 1.20, a change of 0.45. The latest reported quarter, Q2 2026, shows 1.44.
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
J&J reports surgery-comparator benefit for Erleada in prostate cancer
Johnson & Johnson ($JNJ) reported new PROTEUS substudy results comparing Erleada plus hormone therapy before and after prostate surgery with surgery alone. Among 408 patients with high-risk localized or locally advanced disease, the regimen ...
J&J reports early prostate-cancer responses for experimental oral drug
Johnson & Johnson ($JNJ) disclosed early results for oral JNJ-6143 in heavily pretreated advanced prostate cancer. Among 31 evaluable patients receiving 50 milligrams, 77% achieved at least a 50% PSA decline. Confirmed tumor responses occur ...
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...